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Abstract
Objectives: Many cross-sectional and prospective studies
have shown that type 2 diabetes mellitus is a probable
cause of non-alcoholic fatty liver disease (NAFLD) with
fibrosis and cirrhosis. This research aimed to examine the
plasma amino transaminase levels as biomarkers of
NAFLD and their association with apoptosis markers
(Fas and FasL) as well as the lipid profile in type II
diabetic patients.
Methods: This cross-sectional comparative study
included 120 type II diabetic and 100 non-diabetic pa-
tients, and their defined biomarkers were studied.
Results: The results showed that the mean ALT levels,
FasL and triglyceride/high density lipoprotein (TG/
HDL) ratio were significantly higher in patients with type
II diabetics. According to the Atherogenic Index of
Plasma (Log TG/HDL), approximately 45% of diabetic
patients had a high risk and 11% had an intermediatey. This is an open access article under the CC BY-NC-ND license
.1016/j.jtumed.2016.10.002
H.N. Mahran et al. 9risk of developing cardiovascular disease. Alanine
aminotransferase (ALT) was significantly and positively
correlated with FasL, TG, glucose levels and body mass
index (BMI) in diabetic patients. Moreover, TG was
positively correlated with blood glucose levels and BMI,
whereas HDL was negatively correlated with FasL and
ALT.
Conclusion: The results of this study showed that in
diabetic patients, elevated ALT levels and FasL may play
a role in the risk of developing liver disease and could be
used as a distinct marker of NAFLD, indicating liver
injury. Moreover, atherogenic dyslipidaemia is a promi-
nent feature in type II diabetes mellitus. Low HDL-c is
closely associated with hypertriglyceridemia with an
increased risk of cardiovascular disease and NAFLD in
diabetics.
Keywords: Aminotransaminases; Apoptosis; Hyper-
glycaemia; Lipid profile; Type II diabetes mellitus
 2016 The Authors.
Production and hosting by Elsevier Ltd on behalf of Taibah
University. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-
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Over the next 10e20 years, the expansion of diabetes is
estimated to reach pandemic proportions. According to the
World Health Organization, KSA is considered to have the
seventh highest rate of diabetes in the world and the second
highest in the Middle East.1
The damaging effect of diabetes mellitus on the retinal,
renal, nervous and cardiovascular systems is known, but its
influence on the liver has not been firmly established.2
Recently, it has been recognized that hepatic dysfunction in
obesity is associated with oxidative stress and steatosis
accompanying insulin resistance. The resulting consequence
is non-alcoholic fatty liver disease, a familiar spectrum of
disease extending from simple steatosis (fatty infiltration) to
inflammatory steatohepatitis to possible long-term injury
(fibrosis and cirrhosis) and subsequent liver failure.3
Type 2 diabetes is a risk factor for the development of non-
alcoholic fatty liver disease (NAFLD) with fibrosis and
cirrhosis. It is important to note that recognizing type 2 dia-
betic patients who are at risk of acquiring cirrhosis and he-
patocellular carcinoma is very difficult. ALT is the liver
enzyme that is most associated with liver fat accumulation,4
and therefore, ALT has been applied as an indicator of
NAFLD. Some cross-sectional studies have noticed that
ALT is connected to multiple characteristics of metabolic
syndrome. Currently, ALT is frequently applied in epidemi-
ological studies as a substitute indicator for NAFLD.5
Regularly accessible laboratory analysis has been established
to be insufficient, and a variety of scoring systems
constructed on clinical and laboratory considerations have
been suggested, but have not been confirmed as
satisfactorily consistent in assessing individual patients.6 It iswell documented that the presence of insulin metabolic
syndrome (diabetes mellitus, obesity, dyslipidaemia and
hypertension) is associated with a possibly progressive,
severe liver disease. Visceral adipose tissue, which releases
adipokines is a predictor of altered liver function and insulin
resistance. Free fatty acid (FFA) lipolysis from visceral
adipocytes pass through the liver, and because of insulin
resistance, the oxidative capacity is reduced, which leads to
overburdened hepatocytes with fat and hepatic triglyceride
accumulation.7 Necrosis or apoptosis are damaged
hepatocyte responses. The physiological way to remove
injured cells is apoptosis through the FaseFasL mechanism.8
The present study aims to examine the plasma level of the
aminotransaminases (ALT and AST) as markers of non-
alcoholic fatty liver disease (NAFLD) and the levels of
both Fas & FasL as markers of apoptosis as well as their
association with type II diabetic Saudi female patients
compared to healthy females.
Materials and Methods
One-hundred-twenty patients with type 2 diabetes melli-
tus matched for age and sex with one-hundred normal con-
trol subjects enrolled from Prince Maged Ben Abdel Aziz
diabetic centre e Almadinah Almunawwarah, S.A. were
studied in 2015. The exclusion criteria for both diabetic and
control subjects were the following:
 Hypertension (defined as blood pressure greater than 150/
90 mmHg),
 Hypercholesterolaemia (defined as LDL-cholesterol 75
percentile for age and sex),
 Tobacco use within the past 5 years,
 Current use of insulin, anti-oxidants or hormone replace-
ment therapy
 Laboratory evidence of renal, hepatic, or haematological
abnormalities.
 Alcohol use
Consent was obtained from all patients before the
research was conducted.
The two groups were subjected to the following labora-
tory investigations:
1) Estimation of glycated haemoglobin A1C (HbA1C)%
2) Serum glucose concentration determination.
3) Serum liver enzyme ALT and AST concentration
determination.
4) Levels of Fas and FasL determination.
5) Serum lipid profile [Low-density lipoprotein (LDL),
High-density lipoprotein (HDL), Triglycerides (TG) and
total cholesterol] concentration determination.
6) Serum kidney function tests and electrolytes.
Blood collection
Five-millilitre blood samples were collected in plain and
EDTA tubes, and whole blood from the EDTA tubes was
used for HbA1c% estimation. Then, serum separation was
performed for each sample using a centrifuge at 3000 rpm for
5 min to estimate the liver enzymes ALT and AST as well as
Table 1: The mean concentrations ± standard deviation of
Anthropometric data and biochemical data as lipid profile
(LDL, HDL, cholesterol and triglyceride, mmol/L, TG/HDL
ratio), aminotransferase (ALT and AST, U/L), apoptosis
marker (Fas & FasL pg/ml), glycaemic status (fasting glucose
mmol/L & glycated Hb%), kidney function tests and Minerals
in the control group and type II diabetic patients.
Variables Control
n ¼ 100
Mean  SD
Patients
n ¼ 120
Mean  SD
p values
BMI kg/m2 23.01  5.19 32.9  6.52 p< 0.01
Duration of the
disease/years
e 7.41  6.01 e
Age/years 47.25  10.15 53.72  9.82 p ¼ 0.360
LDL mmol/L 2.66  0.63 2.58  0.90 p ¼ 0.823
HDL mmol/L 1.55  0.39 1.16  0.64 p < 0.001
Cholesterol
mmol/L
4.58  0.84 4.57  1.15 p ¼ 0.541
Triglycerides
mmol/L
0.71  0.42 1.82  1.06 p < 0.001
TG/HDL-
atherogenic
dyslipidaemia
0.52  0.47 1.84  1.54 p < 0.001
Glucose mmol/L 5.16  0.41 9.77  4.03 p < 0.001
ALT U/L 34.38  7.3 39.35  12.02 p < 0.001
AST U/L 20.78  5.56 22.51  9.67 p ¼ 0.154
Glycated Hb % e 8.82  1.95 e
Fasting glucose 5.23  0.73 9.66  3.8 p < 0.001
Na (mmol/L) 142.71  3.42 139.6  4.30 p < 0.001
Cl (mmol/L) 103.53  2.22 101.77  11.7 p¼ 0.065
K (mmol/L) 4.2  0.38 4.15  0.42 p¼ 0.299
Ca (mmol/L) 2.25  0.09 2.27  0.100 p¼ 0.592
BUN (mmol/L) 3.79  0.84 4.69  3.6 p¼ 0.160
Creatinine
(mmol/L)
69.87  10.54 72.53  26.70 p¼ 0.193
Uric acid
(mmol/L)
231.28  51.43 238.29  104.58 p¼ 0.59
Fas (pg/ml) 145.14  23.79
(n ¼ 35)
149.80  24.41
(n ¼ 40)
p ¼ 0.508
FasL (pg/ml) 153.90  21.58
(n ¼ 35)
179.36  20.34
(n ¼ 40)
P < 0.01
p < 0.05 consider significance.
Apoptosis, alanine aminotransferase and atherogenic dyslipidaemia in type II diabetes10the lipid profile [LDL, HDL, TG and cholesterol] on the
same day of sampling. Additionally, estimation of fasting
blood glucose was conducted, as well as kidney function tests
andMajor minerals. All of the tests were performed using the
clinical chemistry automated machine Dimension X Pand,
Siemens Healthcare Diagnostics Ltd. (Frimley, Camberley,
UK). Kits, sampling, reagent delivery, mixing, processing
and printing of results were automatically performed by the
Dimension System. The rest of the samples were kept
at 20 for Fas and FasL analyses. Fas and FasL were
determined using Fas enzyme-linked immunosorbent assay
(ELISA) kit (SigmaeAldrich, Saint Louis, U.S.A.), with a
minimum detectable dose of 5 and 2 pg/ml in serum,
respectively. All procedures were performed at room tem-
perature according to the manufacturer’s instructions. Each
sample and standard protein were assayed in duplicate. The
optical density at 450 nm for FasL and Fas was measured
with a spectrophotometric microtiter plate reader (Labsys-
tems iEMS Reader, Helsinki, Finland). A standard curve
obtained with FasL or Fas samples provided with the kit was
used to determine FasL and Fas in each sample.
Statistical analysis
All of the obtained data were subjected to statistical
analysis using SPSS for Windows (version 20, SPSS, Chi-
cago, IL, USA). Data are presented as the means  standard
deviation for continuous variables. Student’s t test was used
for comparison of the baseline continuous characteristics
between the two groups (control and type 2 diabetes). The
correlations were found using the Spearman correlation.
Differences between groups, control group, controlled di-
abetics and uncontrolled diabetics, were tested using one way
analysis of variance (ANOVA) test; p < 0.05 was considered
to be significant. The studied population was divided into six
BMI ranges according to the WHO categorization (<18.5,
18.5e25, 25e30, 30e35, 35e40, and >40 kg/m2).
Results
A total of 120 female diabetic patients with a mean age of
53.72  9.82 years old and mean duration of disease of
7.41 6.01 years were included in the final analysis. They were
compared to 100 healthy control subjects with a mean age of
47.25  10.15, p¼ 0.36. The prevalence of metabolic syn-
drome was 23.5% among diabetic patients, which was deter-
mined by using the National Cholesterol Education Program,
Adult Treatment Panel III (2002 panel guidelines), in which
metabolic syndrome was defined by the presence of three or
more of the following components: abdominal obesity,
hypertriglyceridemia, low HDL-C, high blood pressure, and
high fasting glucose. The results of this study showed that the
ALT levels were significantly higher in type II diabetics
(39.35  12.02) compared to the non-diabetic healthy control
group (34.38 7.3), p< 0.001 (Table 1). Our results revealed a
significant difference in the levels of FasLbetween patients and
the control group (179.36  20.34 vs. 153.90  21.58)
(p < 0.01). The results also showed that the TG
concentration significantly increased in the type II diabetic
group (1.82  1.06) compared with the control group
(0.71  0.42), p < 0.001. The serum high-density lipoprotein(HDL) levels decreased significantly in type II diabetics
compared to the control group (1.16  0.64 vs. 1.55  0.39),
(p < 0.001) (Tables 1 and 2). The TG/HDL ratio significantly
increased in diabetic patients (1.84  1.54) compared to the
control group (0.52  0.47) (p < 0.001) (Table 1). The
Atherogenic Index of Plasma (AIP ¼ Log TG/HDL)
predicts cardiovascular risk, for which AIP < 0.11 indicates
low risk, AIP (0.11e0.21) indicates intermediate risk and
AIP > 0.21 indicates increased risk. In this study, 45% of
our diabetic patients had and increased risk and 11% had an
intermediate risk. Na was significantly lower in diabetic
patients compared to controls (139.6  4.3 vs. 142.71  3.42,
p < 0.001) (Table 1). Correction for the hyperglycaemia
effect on Na levels was applied. Thus, to obtain the “true”
sodium level in cases of extreme hyperglycaemia, the
addition of 2.4 mmol/L to the measured concentration for
every 100 mg/dl increment in plasma glucose above normal
levels was required.9 There were no significant difference in
the levels of Fas, AST, Cl, K, Ca, BUN, creatinine and uric
Table 2: The difference in the mean between the three studied groups: Control group, Controlled diabetics and uncontrolled diabetics in
BMI, ALT, glucose, triglycerides, HDL, Na and FasL. Using ANOVA test, the mean difference between control and diabetic
groups,*p < 0.05, **p < 0.001 and between diabetics groups, -p < 0.05, --p < 0.01.
Biochemical
parameters
Control group
n ¼ 100
(mean  SD)
Controlled
diabetics
n ¼ 18
(mean  SD)
Uncontrolled
diabetics
n ¼ 102
(mean  SD)
BMI 23.01  5.19 30.36  8.37** 31.37  6.4**
ALT 34.38  7.3 35.94  7.11-- 39.96  12.63--**
Glucose 5.23  0.73 5.56  0.75-- 10.52  3.91--**
Triglycerides 0.71  0.42 1.33  0.54-* 1.92  1.11-**
HDL 1.56  0.40 1.13  0.34** 1.16  0.68**
Na 142.71  3.42 140.42  1.62 139.48  4.60**
FasL 153.90  21.58
(n ¼ 35)
177.16  20.49
(n ¼ 6)**
189.26  17.88
(n ¼ 34)**
H.N. Mahran et al. 11acid in type II diabetics compared to the non-diabetic healthy
control group (Tables 1 and 2).
Regarding the correlation between variables, the results
show that in type II diabetic patients, there was a significant
positive correlation found between ALT and FasL, TG,
glucose levels, BMI. A significant negative correlation was
found between HDL and FasL, ALT, TG, glucose levels,
and BMI. Additionally, a significant negative correlation
was found in diabetic patients between Na and ALT, TG,
glucose levels, and glycated Hb% (Figures 1 and 2).
Analysis of the biochemical parameters using ANOVA
revealed a significant difference between the means of the
three groups, control subjects, controlled diabetics and un-
controlled diabetics, for ALT (p < 0.001) and triglycerides
(P< 0.05); between the control and diabetic groups for HDL
(p < 0.001); and between the control subjects and uncon-
trolled diabetic group as well as between the two diabetic
groups for glucose (p< 0.001). The FasL levels were different
in both diabetics and control subjects (p < 0.001). Addi-
tionally, the Na levels were different in uncontrolled di-
abetics and control subjects (p < 0.001). The results0
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Figure 1: The correlation between Alanine aminotransferase
(ALT) and FasL in diabetic patients was a significant positive
correlation (r ¼ 0.385**, p ¼ 0.006).show significant differences in the ALT, TG, HDL, FasL, Na
and glucose mean levels in the three studied groups. In
multivariate analysis, outpatients who were older, had low
high density lipoprotein and showed high blood glucose
levels displayed the most significant clinical explanatory
variables associated with abnormal ALT.
There was a significant difference between patients with
abnormal ALT and normal ALT in glucose concentration,
HDL and Age, Wilk’s l ¼ 0.883, F (3, 107) ¼ 4.714,
p ¼ 0.004 partial h2 ¼ 0.117. A separate ANOVA was con-
ducted for each dependent variable, with each ANOVA
evaluated at an alpha level of 0.025. There was a significant
difference between patients with abnormal ALT and normal
ALT as a function of age, F (1e109) ¼ 7.857, mean-square
error (MSE) ¼ 84.914, p < 0.006, partial h2 ¼ 0.067
(6.7%), and observed Power ¼ 0.793. Patients with elevated
ALT (Mean ¼ 55.54 years) scored higher than normal ALT
patients (Mean ¼ 50.51 years). There was no significant
difference between abnormal ALT patients and normal ALT
patients in glucose levels, F (1e109)¼ 4.250,MSE¼ 16.052,
p < 0.042, Partial h2 ¼ 0.036 (3.6%), observed0
1
2
3
4
5
6
0 50 100
TG
 c
on
ce
nt
ra
Ɵo
n 
(m
m
ol
e/
L)
ALT acƟvity (U/L)
r=  0.252
Figure 2: The correlation between TG concentration and ALT
activity (U/L) in diabetic patients was a significant positive cor-
relation (r ¼ 0.252, p < 0.001).
Apoptosis, alanine aminotransferase and atherogenic dyslipidaemia in type II diabetes12Power ¼ 0.533. Similarly, the ALT levels in diabetic patient
differed insignificantly as a function of the HDL levels, F (1e
109) ¼ 5.056, MSE ¼ 0.085, p < 0.027, Partial h2 ¼ 0.044
(4.4%), and Observed Power ¼ 0.606.
Regarding BMI in the diabetic group, the mean value of
body mass index (BMI) was 32.9  6.52 kg/m2. More than
50% of patients were observed to be obese, with a BMI over
30% in the uncontrolled diabetics, and approximately 42%
of controlled diabetics had a BMI over 30%.Discussion
Elevated ALT and AST were observed in 4.5% and 5.3%
of our diabetic patients, respectively. However, the mean
values were within the normal range. At least 50% of pa-
tients with type 2 diabetes had NAFLD. This result is in
agreement with that of the study by Erbey and his co-worker,
which reported that the prevalence of elevated ALT levels
among U.S. type 2 diabetics was 7.8%, and this prevalence
was higher among obese (BMI > 25 kg/m2) compared to
non-obese diabetics (10.6% vs. 6.6%).10 In support of our
finding regarding ALT elevation in type II diabetic female
patients, the study by Chen et al. found that 3245 adults
suffering from NAFLD had elevated ALT, obesity,
diabetes mellitus, hypercholesterolemia.11 Previous papers
have revealed that the prevalence of NAFLD and its
development to fibrosis and cirrhosis rises with age.12 Our
results are in accordance with those of another study that
reported that elevated ALT levels were significantly related
to a BMI >25 kg/m2 among type 2 diabetics in a study
conducted in India. A positive correlation was also
reported between glycaemic control (FBS and PPBS) and
the duration of diabetes mellitus with ALT levels.13
Our results revealed that there was a significant increase in
FasL in diabetic patients, which indicated an increase in the
rate of apoptosis, similar to another study that revealed
increasing b-cell apoptosis in type II diabetes mellitus.14 It is
known that an increasing rate of apoptosis in b-cells is a
trigger of type II diabetes mellitus.15 Additionally, in
diabetes, reactive oxygen species stimulate the expression
of FasL on hepatocytes, which bind to its receptor (Fas)
on the neighbouring hepatocyte and accelerate apoptosis.16
The association of a microsatellite in FASL to type II
diabetes and of the FAS-670G>A genotype to insulin
resistance was found in another study.15 The non-
significant increase in the levels of Fas in our results could
be explained by the fact that the Fas receptor is not expressed
normally by Islet b-cells and the FasL is expressed nor-
mally.17 Moreover, the expression of the Fas receptor is an
initial measurable indicator of apoptosis compared to
FasL, and most of the patients in our research had
diabetes for a long duration and a high BMI.
A positive correlation existed between FasL and ALT in
our study, as was previously reported by another study in
which the correlation between ALT and the stimulation of
FasL intrahepatic mRNA was observed.18
The prevalence of hypertriglyceridemia in our study in
type 2 diabetic patients was 36% and of low HDL was 41%.
A similar finding was reported for most diabetic patients
with NAFLD. A net retaining of lipids within hepatocytes,
generally in the form of triglycerides, is a requirement for theoccurrence of NAFLD. The abnormal blood lipid compo-
nent is most often associated with obesity and insulin resis-
tance.19 In our investigation, the Triglyceride: HDL ratio
(atherogenic dyslipidaemia) significantly increased in
diabetic patients compared with the control group. Forty-
five percent of our diabetic patients had an increased risk,
and 11% had an intermediate risk of cardiovascular disease
according to the Atherogenic Index of Plasma (Log TG/
HDL), which predicts cardiovascular risk. The atherogenic
lipid profile is often found in patients with type 2 diabetes,
which leads to significant increases in the risk of coronary
heart disease (CHD) in diabetic patients compared with
people without diabetes. The greatest difference between
people with and without diabetes in lipid profile occurs in
triglycerides and high-density lipoprotein cholesterol (HDL).
HDL tends to be lower in patients with diabetes, whereas
triglycerides markedly increase. However, the atherogenic
form of LDL is more likely to be found in patients with type
2 diabetes than people without diabetes. Additionally, low
HDL levels restrict reverse cholesterol transport, which is
usually associated with diabetes and may also be associated
with increased lipid oxidation.20
Regarding the hyponatremia noticed in this study, dia-
betes is considered to be a disorder with an increased elec-
trolyte imbalance because of the influences of impaired renal
function, acid-base disorders, malabsorption syndromes and
multidrug treatments (which often exists in diabetics).21
Osmotic diuresis frequently occurs in uncontrolled DM and
may additionally cause hypovolemic-hyponatremia. Forced
urinary electrolyte losses and aggravation of renal sodium
loss occurs in diabetic ketoacidosis as a result of ketone
bodies (b-hydroxybutyrate and acetoacetate).22 The changed
metabolism of vasopressin, communication between
vasopressin and insulin (both hormones work in the renal
collecting duct), and reabsorption of more hypotonic fluid
due to delayed stomach emptying have been suggested as
likely important mechanisms of this association.23
Conclusion
ALT and FasL were the variables that were most strongly
associated with diabetes mellitus. NAFLD is the most
common cause of a mild elevation of serumALT and also the
most prevalent liver disease in type 2 diabetes. The Trigly-
ceride:HDL ratio (atherogenic dyslipidaemia) significantly
increased in diabetic patients. This ratio was most related to
diabetic patients with older age, long duration of the disease
and increased glucose levels. These data support a possible
contribution of hyperglycaemia (glycaemic status) in type 2
diabetics to the pathogenesis of hypertriglyceridemia and
atherogenic dyslipidaemia. Additionally, he ALT and FasL
levels play a role in the risk of developing liver disease and
can be used as markers for NAFLD.
Therapy to inhibit apoptosis may be important in treating
type II diabetes, especially its complications.
Recommendations
Based on this research, it is recommended to determine
the levels of ALT and FasL in type 2 diabetes patients
because they are good indicators of NAFLD. Developing a
H.N. Mahran et al. 13treatment to increase B-cell apoptosis in patients with type 2
diabetes may slow progression to NAFLD.
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